VR Logo

Unrated

Tata India Pharma & HealthCare Fund - Direct Plan


Equity: Sectoral-Pharma

1 Lakh

Investment Grown to
₹ 1.33 Lakh

₹ 10000

Monthly SIP Grown to
₹ 4.64 Lakh

Suitability:

This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.

We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in multi cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.

But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.

Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.

Taxability of earnings:

Capital gains

  • If the mutual fund units are sold after 1 year from the date of investment, gains upto Rs 1 lakh in a financial year are exempt from tax. Gains over Rs 1 lakh are taxed at the rate of 10%.
  • If the mutual fund units are sold within 1 year from the date of investment, entire amount of gain is taxed at the rate of 15%.
  • No tax is to be paid as long as you continue to hold the units.

Dividends

  • Dividends paid by the mutual fund scheme are taxed at the rate of 10% (effectively 11.648%, including surcharge and cess). This is known as Dividend Distribution Tax (DDT). Though the investor does not pay this tax directly, it is deducted from the dividend income before passing on to the investor.

Read more

ajax-loader
Please wait...

ajax-loader
Please wait...

(₹)
cal
cal

ajax-loader
Please wait...

Trailing Returns (%)

YTD 1-Day 1-W 1-M 3-M 6-M 1-Y 3-Y 5-Y 7-Y 10-Y
Fund 23.71 -0.17 1.37 0.23 6.21 21.50 30.22 10.01 -- -- --
S&P BSE Healthcare TRI 24.64 0.01 2.38 3.36 12.88 22.13 30.08 5.05 -- -- --
Equity: Sectoral-Pharma 26.81 0.05 1.86 2.20 10.60 23.85 36.71 9.60 -- -- --
Rank within category 8 9 7 9 9 8 8 2 -- -- --
Number of funds in category 9 9 9 9 9 9 9 4 3 3 0

As on 14-Jul-2020

Peer Comparison

Fund name Rating Launch Date 1-Year Return 3-Year Return 5-Year Return Expense Ratio Assets (Cr)
Tata India Pharma & HealthCare Fund - Direct Plan  | Invest Online
Unrated
Dec-15 30.22 10.01 -- 1.20 241
Nippon India Pharma Fund - Direct Plan
Unrated
Jan-13 36.38 13.90 7.85 1.35 3,093
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund - Direct Plan  | Invest Now
Unrated
Jul-18 39.08 -- -- 1.37 1,523
SBI Healthcare Opportunities Fund - Direct Plan  | Invest Online
Unrated
Jan-13 37.30 5.97 1.46 1.24 1,154
Mirae Asset Healthcare Fund - Direct Plan  | Invest Online
Unrated
Jul-18 44.04 -- -- 0.83 640

Best & Worst Performance

Best (Period) Worst (Period)
Week 20.45 (01-Apr-2020 - 09-Apr-2020) -11.10 (05-Mar-2020 - 12-Mar-2020)
Month 31.75 (27-Mar-2020 - 27-Apr-2020) -18.30 (20-Feb-2020 - 23-Mar-2020)
Quarter 38.52 (23-Mar-2020 - 22-Jun-2020) -14.24 (26-Sep-2016 - 26-Dec-2016)
Year 37.43 (24-Jun-2019 - 23-Jun-2020) -17.32 (08-Sep-2016 - 08-Sep-2017)

Risk Measures (%)

Mean Std Dev Sharpe Sortino Beta Alpha
Fund 11.74 19.27 0.33 0.60 0.81 4.48
S&P BSE Healthcare TRI 7.72 22.96 0.11 0.24 -- --
Equity: Sectoral-Pharma 11.34 20.12 0.30 0.63 0.85 3.99
Rank within category 2 1 2 2 1 2
Number of funds in category 4 4 4 4 4 4

The Risk Measures have been calculated using calendar month returns for the last three years.

As on 30-Jun-2020

Asset Allocation (%)

ajax-loader
Please wait...

Concentration & Valuation

Number of Stocks 19
Top 10 Stocks (%) 82.46
Top 5 Stocks (%) 57.85
Top 3 Sectors (%) 98.49
Portfolio P/B Ratio 3.89
Portfolio P/E Ratio 32.59

Portfolio Aggregates

Fund Category
Average Mkt Cap (Rs Cr) 35,758 28,993
Giant (%) 17.34 10.94
Large (%) 49.82 46.71
Mid (%) 20.39 27.43
Small (%) 12.45 14.92
Tiny (%) -- --

Value Research Fund Style

Sector Allocation vis-à-vis Category

ajax-loader
Please wait...

Top Holdings

Company Sector P/E 3Y High 3Y Low % Assets
up Sun Pharmaceutical Inds. Healthcare 31.62 23.13 5.93 17.08
up Dr. Reddy's Lab Healthcare 33.08 17.99 0.00 16.04
equal Divi's Laboratories Healthcare 43.18 10.88 0.00 9.69
down Lupin Healthcare -- 10.47 0.00 8.44
equal Ipca Laboratories Healthcare 34.35 11.01 2.32 6.60
up Cipla Healthcare 33.28 8.03 0.00 6.11
equal Aurobindo Pharma Healthcare 17.27 8.81 0.00 5.60
equal Procter & Gamble Health Healthcare 41.04 7.30 0.00 4.39
equal Narayana Hrudayalaya Healthcare 48.05 4.87 0.00 4.26
equal Abbott India Healthcare 54.55 11.41 1.74 4.24
equal Cadila Healthcare Healthcare 30.97 8.35 0.00 3.18
new Natco Pharma Healthcare 26.32 8.66 0.00 2.62
equal Healthcare Global Enterprises Healthcare -- 5.13 0.00 2.09
down Alembic Pharmaceuticals Healthcare 21.83 5.76 1.84 1.84
equal Apollo Hospitals Healthcare 44.68 6.51 1.82 1.82
new Indoco Remedies Healthcare 76.91 1.52 0.00 1.52
equal Syngene International Healthcare 41.02 7.99 0.00 1.38
equal Dr. Lal Pathlabs Healthcare 70.81 1.38 0.00 0.84
equal Astrazeneca Pharma India Healthcare 114.91 0.80 0.00 0.74

up down equal Indicates an increase or decrease or no change in holding since last portfolio
new Indicates a new holding since last portfolio

As on 30-Jun-2020

Fund Manager

— Sailesh Jain since 09-Nov-2018

Education: Mr. Jain is a Commerce Graduate and an MBA.

Experience: Prior to joining TATA Mutual Fund, he has worked with Invesco Mutual Fund, IDFC Securities Ltd. as Head Derivatives, Quant Broking Pvt Ltd. as Vice President and IIFL(India Infoline) as Vice President.

Funds Managed:

— Meeta Shetty since 09-Nov-2018

Education: Ms. Shetty is Bachelor in Economics and CFA Charterholder

Experience: Prior to joining TATA Mutual Fund, she has worked with Kotak Securities, HDFC Securities, AMSEC(Asian Market Securities), Dalal & Broacha Stock Broking and karvey Stock Broking.

Funds Managed:


-0.17%

Change from previous, NAV as on 14-Jul-2020

Growth: ₹ 12.1866

Dividend: ₹ 12.1866


Investment Strategy

The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.

Investment Details

Minimum Investment (₹) 5,000
Minimum Addl Investment (₹) 1,000
Minimum SIP Investment (₹) 150
Minimum No of Cheques 12
Minimum Withdrawal (₹) 500
Minimum Balance (₹) 500
Exit Load 0.25% for redemption within 91 days

Basic Details

Fund House: Tata Mutual Fund
Launch Date: 28-Dec-2015
Return Since Launch: 4.44%
Benchmark: NIFTY Pharma TRI
Riskometer: High
Type: Open-ended
Assets: ₹ 241 Cr (As on 30-Jun-2020)
Expense: 1.20% (As on 31-May-2020)
Risk Grade: --
Return Grade: --
Turnover: 46.42%

Contact Information

AMC: Tata Asset Management Private Ltd

Address: 9th Floor, Mafatlal Centre, Nariman Point, Mumbai - 400021

Phone: 1800-209-0101

Email: [email protected]

Website: http://www.tatamutualfund.com

Registrar & Transfer Agent: Computer Age Management Services Ltd.

Address: 7th Floor, Tower II, Rayala Towers, 158, Anna Salai, Chennai - 600002

Phone: 1800-3010-6767 / 1800-419-7676

Fax: 044-30407101

Email: [email protected]

Website: www.camsonline.com

Upcoming Video

Value Investing

Evaluating Covid-affected financials of India Inc

dateFriday, 17-Jul-2020
time12:30 PM - 01:00 PM